# Oruka Therapeutics, Inc.: Form 8-K, filed Sep 5, 2024

- Company: [Oruka Therapeutics, Inc.](/companies/orka.md) (CIK 907654)
- Form: 8-K
- Filed: 2024-09-05
- Accepted by EDGAR: Sep 5, 2024, 17:18 ET
- Period: 2024-08-29
- Accession: 0001213900-24-076184
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/907654/000121390024076184/ea0213193-8k_orukathera.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/907654/000121390024076184/

## Items reported

- Item 1.01: Entry into a material agreement
- Item 2.01: Completion of an acquisition or disposition
- Item 2.02: Results of operations
- Item 3.03: Change to security holders’ rights
- Item 4.01: Change of auditor
- Item 5.01: Change in control
- Item 5.02: Departure or appointment of officers or directors
- Item 5.03: Amendment to articles or bylaws
- Item 5.05: Item not in the standard list
- Item 5.06: Item not in the standard list
- Item 7.01: Regulation FD disclosure
- Item 9.01: Financial statements and exhibits

## Sections

Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. https://www.sec.gov/Archives/edgar/data/907654/000121390024076184/ea0213193-8k_orukathera.htm

Filed Sep 5, 2024.
Source: SEC EDGAR, the filing index for accession 0001213900-24-076184. Last ingested by Listed: Nov 10, 2026, 01:43 ET. No prices; not investment advice.